Equities Analysts Offer Predictions for CRSP Q4 Earnings

Key Points

• HC Wainwright has raised its Q4 2025 EPS estimate for CRISPR Therapeutics to ($0.99), improving from a previous forecast of ($1.02), while maintaining a "Buy" rating and a price target of $80.00.
• The company reported a quarterly earnings per share of ($1.29), beating expectations by $0.18, but its revenue of $0.89 million fell short of the anticipated $6.44 million.
• Despite recent earnings news, the stock has a consensus rating of "Hold" with an average price target of $71.60, while trading at around $55.00.

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Research analysts at HC Wainwright upped their Q4 2025 earnings per share (EPS) estimates for shares of CRISPR Therapeutics in a report issued on Thursday, August 7th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of ($0.99) per share for the quarter, up from their previous estimate of ($1.02). HC Wainwright currently has a "Buy" rating and a $80.00 price target on the stock. The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share. HC Wainwright also issued estimates for CRISPR Therapeutics' Q1 2026 earnings at ($0.99) EPS, Q2 2026 earnings at ($0.90) EPS, Q3 2026 earnings at ($0.90) EPS, Q4 2026 earnings at ($0.82) EPS and FY2026 earnings at ($3.61) EPS.

Several other research firms have also weighed in on CRSP. Royal Bank Of Canada boosted their target price on CRISPR Therapeutics from $38.00 to $42.00 and gave the stock a "sector perform" rating in a report on Tuesday, August 5th. Needham & Company LLC restated a "buy" rating and issued a $81.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, July 8th. Chardan Capital restated a "buy" rating and issued a $82.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, August 5th. Bank of America cut their price target on CRISPR Therapeutics from $79.00 to $78.00 and set a "buy" rating for the company in a report on Tuesday, July 22nd. Finally, JMP Securities reiterated a "market outperform" rating and set a $86.00 price target on shares of CRISPR Therapeutics in a report on Friday, June 27th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $71.60.

CRISPR Therapeutics Price Performance

CRSP traded up $2.27 on Monday, hitting $61.09. The company had a trading volume of 726,307 shares, compared to its average volume of 2,610,633. The company's fifty day moving average price is $53.14 and its 200 day moving average price is $44.29. CRISPR Therapeutics has a 1-year low of $30.04 and a 1-year high of $71.13. The stock has a market cap of $5.56 billion, a price-to-earnings ratio of -11.26 and a beta of 1.80.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its earnings results on Monday, August 4th. The company reported ($1.29) earnings per share for the quarter, topping the consensus estimate of ($1.47) by $0.18. CRISPR Therapeutics had a negative return on equity of 20.05% and a negative net margin of 1,229.43%. The firm had revenue of $0.89 million during the quarter, compared to analyst estimates of $6.44 million. During the same period in the previous year, the company earned ($1.49) EPS. The company's revenue for the quarter was up 72.5% on a year-over-year basis.

Insider Buying and Selling

In other news, insider Naimish Patel sold 3,932 shares of the business's stock in a transaction that occurred on Thursday, May 29th. The stock was sold at an average price of $35.94, for a total transaction of $141,316.08. Following the sale, the insider directly owned 6,068 shares in the company, valued at approximately $218,083.92. The trade was a 39.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Simeon George acquired 989,812 shares of the stock in a transaction dated Wednesday, July 16th. The shares were purchased at an average price of $52.03 per share, for a total transaction of $51,499,918.36. Following the completion of the transaction, the director owned 1,730,179 shares of the company's stock, valued at $90,021,213.37. This trade represents a 133.69% increase in their position. The disclosure for this purchase can be found here. Insiders own 4.30% of the company's stock.

Institutional Trading of CRISPR Therapeutics

A number of large investors have recently bought and sold shares of CRSP. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in CRISPR Therapeutics by 182.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,952,751 shares of the company's stock valued at $66,452,000 after acquiring an additional 1,262,560 shares during the period. ARK Investment Management LLC grew its position in CRISPR Therapeutics by 13.3% in the first quarter. ARK Investment Management LLC now owns 10,165,400 shares of the company's stock valued at $345,929,000 after acquiring an additional 1,192,336 shares during the period. T. Rowe Price Investment Management Inc. grew its position in CRISPR Therapeutics by 39.2% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company's stock valued at $150,029,000 after acquiring an additional 1,074,238 shares during the period. Geode Capital Management LLC grew its position in CRISPR Therapeutics by 98.1% in the second quarter. Geode Capital Management LLC now owns 2,071,883 shares of the company's stock valued at $100,789,000 after acquiring an additional 1,025,979 shares during the period. Finally, State Street Corp grew its position in CRISPR Therapeutics by 35.6% in the second quarter. State Street Corp now owns 3,270,596 shares of the company's stock valued at $159,082,000 after acquiring an additional 859,334 shares during the period. 69.20% of the stock is currently owned by institutional investors.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.